Baidu
map

Retin Cases Brief Rep.:使用INVITRIA注射指南后出现气泡相关眼内炎!

2017-09-05 cuiguizhong MedSci原创

英国伦敦皇家自由医院眼科系的Baneke AJ近日在Retin Cases Brief Rep发表了他们团队近期的一项工作,他们按照InVitria注射操作规范进行玻璃体内注射后,发现一例患者出现与气泡相关的眼内炎的情况,他们也对气泡相关的眼内炎的研究进行了综述。

英国伦敦皇家自由医院眼科系的Baneke AJ近日在Retin Cases Brief Rep发表了他们团队近期的一项工作,他们按照InVitria注射操作规范进行玻璃体内注射后,发现一例患者出现与气泡相关的眼内炎的情况,他们也对气泡相关的眼内炎的研究进行了综述。经过文献查阅,结果他们发现,在青光眼手术5年内,气泡相关的眼内炎发生率高达2%。 危险因素包括气泡渗漏,抗纤维蛋白溶解剂的使用,眼睑炎,低血压和鼻泪管阻塞。 按照InVitria注射指南操作,玻璃体内注射2周后,他们的患者出现了气泡漏气和气泡相关眼内炎的情况。因此,他们认为,注射操作指南可能引起气泡创伤并导致气泡渗漏。 在筛选青光眼手术患者时应尽量避免此类事件。原文出处:Baneke, A.J., et al., BLEB-RELATED ENDOPHTHALMITIS AFTER USE OF THE INVITRIA INJECTION GUIDE. Retin Cases Brief Rep, 2017.本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2027925, encodeId=2ba4202e925fe, content=<a href='/topic/show?id=7c9a41324e' target=_blank style='color:#2F92EE;'>#case#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4132, encryptionId=7c9a41324e, topicName=case)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Jan 30 09:50:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693384, encodeId=f00c169338436, content=<a href='/topic/show?id=84a9e272175' target=_blank style='color:#2F92EE;'>#眼内炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72721, encryptionId=84a9e272175, topicName=眼内炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ee29418707, createdName=liuyong2990, createdTime=Sun Mar 04 01:50:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913842, encodeId=469f1913842b4, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Mar 07 02:50:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569713, encodeId=11021569e1303, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Thu Sep 07 11:50:00 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624841, encodeId=da381624841b4, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Thu Sep 07 11:50:00 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
    2018-01-30 charl1234567
  2. [GetPortalCommentsPageByObjectIdResponse(id=2027925, encodeId=2ba4202e925fe, content=<a href='/topic/show?id=7c9a41324e' target=_blank style='color:#2F92EE;'>#case#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4132, encryptionId=7c9a41324e, topicName=case)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Jan 30 09:50:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693384, encodeId=f00c169338436, content=<a href='/topic/show?id=84a9e272175' target=_blank style='color:#2F92EE;'>#眼内炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72721, encryptionId=84a9e272175, topicName=眼内炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ee29418707, createdName=liuyong2990, createdTime=Sun Mar 04 01:50:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913842, encodeId=469f1913842b4, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Mar 07 02:50:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569713, encodeId=11021569e1303, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Thu Sep 07 11:50:00 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624841, encodeId=da381624841b4, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Thu Sep 07 11:50:00 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2027925, encodeId=2ba4202e925fe, content=<a href='/topic/show?id=7c9a41324e' target=_blank style='color:#2F92EE;'>#case#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4132, encryptionId=7c9a41324e, topicName=case)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Jan 30 09:50:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693384, encodeId=f00c169338436, content=<a href='/topic/show?id=84a9e272175' target=_blank style='color:#2F92EE;'>#眼内炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72721, encryptionId=84a9e272175, topicName=眼内炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ee29418707, createdName=liuyong2990, createdTime=Sun Mar 04 01:50:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913842, encodeId=469f1913842b4, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Mar 07 02:50:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569713, encodeId=11021569e1303, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Thu Sep 07 11:50:00 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624841, encodeId=da381624841b4, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Thu Sep 07 11:50:00 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
    2018-03-07 ysjykql
  4. [GetPortalCommentsPageByObjectIdResponse(id=2027925, encodeId=2ba4202e925fe, content=<a href='/topic/show?id=7c9a41324e' target=_blank style='color:#2F92EE;'>#case#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4132, encryptionId=7c9a41324e, topicName=case)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Jan 30 09:50:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693384, encodeId=f00c169338436, content=<a href='/topic/show?id=84a9e272175' target=_blank style='color:#2F92EE;'>#眼内炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72721, encryptionId=84a9e272175, topicName=眼内炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ee29418707, createdName=liuyong2990, createdTime=Sun Mar 04 01:50:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913842, encodeId=469f1913842b4, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Mar 07 02:50:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569713, encodeId=11021569e1303, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Thu Sep 07 11:50:00 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624841, encodeId=da381624841b4, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Thu Sep 07 11:50:00 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
    2017-09-07 dongjia2015
  5. [GetPortalCommentsPageByObjectIdResponse(id=2027925, encodeId=2ba4202e925fe, content=<a href='/topic/show?id=7c9a41324e' target=_blank style='color:#2F92EE;'>#case#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4132, encryptionId=7c9a41324e, topicName=case)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Jan 30 09:50:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693384, encodeId=f00c169338436, content=<a href='/topic/show?id=84a9e272175' target=_blank style='color:#2F92EE;'>#眼内炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72721, encryptionId=84a9e272175, topicName=眼内炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ee29418707, createdName=liuyong2990, createdTime=Sun Mar 04 01:50:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913842, encodeId=469f1913842b4, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Wed Mar 07 02:50:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569713, encodeId=11021569e1303, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Thu Sep 07 11:50:00 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624841, encodeId=da381624841b4, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Thu Sep 07 11:50:00 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
    2017-09-07 yaanren

相关资讯

Korean J Ophthalmol :眼内炎综述

台湾高雄退伍军人综合医院眼科系的Sheu SJ近日在Korean J Ophthalmol. 发表了一篇综述,系统的阐述了目前眼内炎分类、临床诊断和治疗,对未来可能的治疗方案也进行了论述。

Rheumatol Int:治疗贝切特氏病相关葡萄膜炎的生物疗法综述!

意大利锡耶纳大学风湿病眼科协作葡萄膜炎中心的Sota J近日在Korean J Ophthalmol 发表了一篇综述,系统的阐述了眼内炎治疗药物的现状,也指出其他可能的潜在治疗药物。

Medicine:丙泊酚全凭静脉麻醉并不会增加眼部手术术后眼内炎的发生率

既往研究表明,患者在全麻(GA)下接受眼部手术后患者的鼻咽分泌物会留在脸上,特别是在丙泊酚全静脉麻醉(TIVA),这可能会导致术后眼内炎。因此,本文进行了一项回顾性研究以对比眼部手术采用局麻、吸入麻醉以及TIVA术后眼内炎的发生率。 研究纳入了2011年至2015年就诊于本医疗中心的21032名患者。研究人员评估了流行病学因素、系统性疾病,以及其他眼部病理特征,术中并发症,眼外科技术,预防性

Baidu
map
Baidu
map
Baidu
map